ESMO 2023
Oct 20 - 24, 2023 | Madrid, Spain
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2-Advanced Breast Cancer: Update of Dose Escalation Results From a Phase 1/2 TrialEP Hamilton et al.
Poster
Phase 1/2 Study of Bavdegalutamide, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Radiographic Progression-Free Survival in Patients With Androgen Receptor Ligand-Binding Domain MutationDP Petrylak et al.